A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
NCT #
NCT03785249
Condition(s)
Solid Tumor
Molecular Target(s)
KRAS G12, KRAS G12C, KRAS MUTATION
Drug Classification(s)
Small Molecule Inhibitor
Agents(s)
Adagrasib (MRTX849)
Phase(s)
I/II
Mechanism of Action
Adagrasib is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C).
mutation (G12C).
Purpose
- How much of the study drug can be given with an acceptable level of side effects when given alone or in combination with Pembrolizumab, Cetuximab or Afatinib
- The effects of the study drug (good and bad) when given alone or in combination with Pembrolizumab, Cetuximab or Afatinib
- How much of the study drug is absorbed into the blood and how fast it is removed when given alone or in combination with Pembrolizumab, Cetuximab or Afatinib
- If research tests can be used in the future to predict who will benefit from the study drug
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
JIT-TSC-007
n/a
Molecular Targeted Therapy
TSC1, TSC2
Solid Tumor
No
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.